Home / CXCL13/BLC/BCA-1 / Human CXCL13/BLC/BCA-1 Antibody

Human CXCL13/BLC/BCA-1 Antibody

Catalog #: AF801
39 Citations 5 Reviews Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
AF801
AF801-SP
Chemotaxis Induced by CXCL13/BLC/BCA‑1 and Neutralization by Human CXCL13/BLC/BCA‑1 Antibody.
3 Images
Product Details
Citations (39)
FAQs
Supplemental Products
Reviews (5)
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human CXCL13/BLC/BCA-1 Antibody Summary

Species Reactivity
Human
Specificity
Detects CXCL13/BLC/BCA‑1 in direct ELISAs and Western blots. 
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
E. coli-derived recombinant human CXCL13/BCA-1
Val23-Arg94
Accession # Q53X90
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
0.1 µg/mL
Recombinant Human CXCL13/BLC/BCA‑1 (Catalog # 801-CX)
Immunohistochemistry
5-15 µg/mL
See below
Dual RNAscope ISH-IHC
5-15 µg/mL
Immersion fixed paraffin-embedded sections of human lymphoma
Neutralization
Measured by its ability to neutralize CXCL13/BLC/BCA‑1-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR5. The Neutralization Dose (ND50) is typically 1-4 µg/mL in the presence of 50 ng/mL Recombinant Human CXCL13/BLC/BCA‑1.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization Chemotaxis Induced by CXCL13/BLC/BCA‑1 and Neutralization by Human CXCL13/BLC/BCA‑1 Antibody. View Larger

Chemotaxis Induced by CXCL13/BLC/BCA‑1 and Neutralization by Human CXCL13/BLC/BCA‑1 Antibody. Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin. Chemotaxis elicited by Recombinant Human CXCL13/BLC/BCA-1 (50 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human CXCL13/BLC/BCA-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF801). The ND50 is typically 1-4 µg/mL.

Immunohistochemistry CXCL13/BLC/BCA-1 antibody in Human Lymphoma by Immunohistochemistry (IHC-P). View Larger

CXCL13/BLC/BCA‑1 in Human Lymphoma. CXCL13/BLC/BCA-1 was detected in immersion fixed paraffin-embedded sections of human lymphoma using Goat Anti-Human CXCL13/BLC/BCA-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF801) at 10 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

In-situ Hybridization View Larger

Detection of CXCL13/BLC/BCA‑1 in Human Lymphoma. Formalin-fixed paraffin-embedded tissue sections of Hodgkin’s Lymphoma were probed for CXCL13 mRNA (ACD RNAScope Probe, catalog # 311321; Fast Red chromogen, ACD catalog # 322360). Adjacent tissue section was processed for immunohistochemistry using goat anti-human CXCL13 polyclonal antibody (R&D Systems catalog # AF801) at 5ug/mL with 1-hour incubation at room temperature followed by incubation with anti-goat IgG VisUCyte HRP Polymer Antibody (Catalog # VC004) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL13/BLC/BCA-1

CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23‑34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.

References
  1. Gunn, M.D. et al. (1998) Nature, 391:799.
  2. Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
  3. Forster, R. et al. (1996) Cell 87:1037.
Entrez Gene IDs
10563 (Human); 55985 (Mouse)
Alternate Names
ANGIE; ANGIE2; B cell-attracting chemokine 1; B lymphocyte chemoattractant; BCA1; BCA-1; BCA1B-cell chemoattractant; BCA-1CXC chemokine BLC; B-cell-homing chemokine (ligand for Burkitt's lymphoma receptor-1); BLC; BLCSmall-inducible cytokine B13; BLR1L; B-lymphocyte chemoattractant; chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant); chemokine (C-X-C motif) ligand 13; C-X-C motif chemokine 13; CXCL13; SCYB13; SCYB13B-cell-attracting chemokine 1; small inducible cytokine B subfamily (Cys-X-Cys motif), member 13 (B-cellchemoattractant)

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human CXCL13/BLC/BCA-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

39 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells
    Authors: Guangchao Li, Jintao Guo, Yanfang Zheng, Wen Ding, Zheping Han, Lingyu Qin et al.
    Molecular Therapy - Oncolytics
  2. CXCL13 expression in mouse 4T1 breast cancer microenvironment elicits antitumor immune response by regulating immune cell infiltration
    Authors: Qizhi Ma, Yue Chen, Qing Qin, Fuchun Guo, Yong-sheng Wang, Dan Li
    Precision Clinical Medicine
  3. Macaque Paneth Cells Express Lymphoid Chemokine CXCL13 and Other Antimicrobial Peptides Not Previously Described as Expressed in Intestinal Crypts.
    Authors: Lucero CM, Fallert Junecko B, Klamar CR et al.
    Clin Vaccine Immunol
  4. Circulating (CD3(-)CD19(+)CD20(-)IgD(-)CD27(high)CD38(high)) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?
    Authors: Agnieszka Pozdzik, Ingrid Beukinga, Chunyan Gu-Trantien, Karen Willard-Gallo, Joëlle Nortier, Olivier Pradier
    Mediators of Inflammation
  5. CD4+ follicular helper T cell infiltration predicts breast cancer survival
    Authors: Chunyan Gu-Trantien, Sherene Loi, Soizic Garaud, Carole Equeter, Myriam Libin, Alexandre de Wind et al.
    Journal of Clinical Investigation
  6. Tertiary Lymphoid Organs in Lymphatic Malformations
    Authors: Andrew L. Kirsh, Sharon L. Cushing, Eunice Y. Chen, Stephen M. Schwartz, Jonathan A. Perkins
    Lymphatic Research and Biology
  7. Lymphoid Aggregates That Resemble Tertiary Lymphoid Organs Define a Specific Pathological Subset in Metal-on-Metal Hip Replacements
    Authors: Saloni Mittal, Matthew Revell, Francesca Barone, Debbie L. Hardie, Gulraj S. Matharu, Alison J. Davenport et al.
    PLoS ONE
  8. A new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis
    Authors: Wanting Liu, Yonghong Peng, Desmond J. Tobin
    PeerJ
  9. TNF-&alpha and IL-10 Control CXCL13 Expression in Human Macrophages
    Authors: N Bellamri, R Viel, C Morzadec, V Lecureur, A Joannes, B de Latour, F Llamas-Gut, L Wollin, S Jouneau, L Vernhet
    J. Immunol., 2020-03-25;0(0):.
  10. IL-35 producing B cells promote the development of pancreatic neoplasia
    Authors: Yuliya Pylayeva-Gupta, Shipra Das, Jesse S. Handler, Cristina H. Hajdu, Maryaline Coffre, Sergei B. Koralov et al.
    Cancer Discovery
  11. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer
    Authors: Di Modugno, F;Di Carlo, A;Spada, S;Palermo, B;D'Ambrosio, L;D'Andrea, D;Morello, G;Belmonte, B;Sperduti, I;Balzano, V;Gallo, E;Melchionna, R;Panetta, M;Campo, G;De Nicola, F;Goeman, F;Antoniani, B;Carpano, S;Frigè, G;Warren, S;Gallina, F;Lambrechts, D;Xiong, J;Vincent, BG;Wheeler, N;Bortone, DS;Cappuzzo, F;Facciolo, F;Tripodo, C;Visca, P;Nisticò, P;
    EBioMedicine
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  12. Comparison of Follicular Helper T-Cell Markers with the Expression of the Follicular Homing Marker CXCR5 in Peripheral T-Cell Lymphomas-A Reappraisal of Follicular Helper T-Cell Lymphomas
    Authors: Krenács, L;Krenács, D;Borbényi, Z;Tóth, E;Nagy, A;Piukovics, K;Bagdi, E;
    International journal of molecular sciences
    Species: Human
    Sample Types: Whole Tissue
    Applications: Immunohistochemistry
  13. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
    Authors: SK Pierson, L Katz, R Williams, M Mumau, M Gonzalez, S Guzman, A Rubenstein, AB Oromendia, P Beineke, A Fosså, F van Rhee, DC Fajgenbaum
    Nature Communications, 2022-11-24;13(1):7236.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  14. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity
    Authors: M Uzzan, JC Martin, L Mesin, AE Livanos, T Castro-Dop, R Huang, F Petralia, G Magri, S Kumar, Q Zhao, AK Rosenstein, M Tokuyama, K Sharma, R Ungaro, R Kosoy, D Jha, J Fischer, H Singh, ME Keir, N Ramamoorth, WEO Gorman, BL Cohen, A Rahman, F Cossarini, A Seki, L Leyre, ST Vaquero, S Gurunathan, EK Grasset, B Losic, M Dubinsky, AJ Greenstein, Z Gottlieb, P Legnani, J George, H Irizar, A Stojmirovi, C Brodmerkel, A Kasarkis, BE Sands, G Furtado, SA Lira, ZK Tuong, HM Ko, A Cerutti, CO Elson, MR Clatworthy, M Merad, M Suárez-Far, C Argmann, JA Hackney, GD Victora, GJ Randolph, E Kenigsberg, JF Colombel, S Mehandru
    Nature Medicine, 2022-02-21;0(0):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  15. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response
    Authors: J He, X Xiong, H Yang, D Li, X Liu, S Li, S Liao, S Chen, X Wen, K Yu, L Fu, X Dong, K Zhu, X Xia, T Kang, C Bian, X Li, H Liu, P Ding, X Zhang, Z Liu, W Li, Z Zuo, P Zhou
    Cell Research, 2022-02-14;0(0):.
    Species: Xenograft
    Sample Types: Whole Tissue
    Applications: IHC
  16. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
    Authors: D Phillips, M Matusiak, BR Gutierrez, SS Bhate, GL Barlow, S Jiang, J Demeter, KS Smythe, RH Pierce, SP Fling, N Ramchurren, MA Cheever, Y Goltsev, RB West, MS Khodadoust, YH Kim, CM Schürch, GP Nolan
    Nature Communications, 2021-11-18;12(1):6726.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  17. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
    Authors: N van Dijk, A Gil-Jimene, K Silina, K Hendrickse, LA Smit, JM de Feijter, ML van Montfo, C van Rooije, D Peters, A Broeks, HG van der Po, A Bruining, Y Lubeck, K Sikorska, TN Boellaard, P Kvistborg, DJ Vis, E Hooijberg, TN Schumacher, M van den Br, LFA Wessels, CU Blank, BW van Rhijn, MS van der He
    Nat Med, 2020-10-12;0(0):.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  18. Histopathology and expression of the chemokines CXCL10, CXCL13, and CXCR3 and the endogenous TLR-4 ligand S100A8/A9 in lymph nodes of patients with adult-onset Still's disease
    Authors: HA Kim, YH Kim, YK Jeon, WI Yang, JE Kwon, JH Han
    Sci Rep, 2019-05-17;9(1):7517.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  19. Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy
    Authors: C Liu, X Huang, M Werner, R Broering, J Ge, Y Li, B Liao, J Sun, J Peng, M Lu, J Hou, X Zhang
    Front Immunol, 2017-03-23;8(0):323.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  20. Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia
    Cancer Discov, 2015-12-29;6(3):256-69.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  21. CXCL13 antibody for the treatment of autoimmune disorders.
    Authors: Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M, Jonason A, Mallow C, Doherty M, Paris M, Smith E, Zauderer M
    BMC Immunol, 2015-02-12;16(0):6.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  22. Control of the T follicular helper-germinal center B-cell axis by CD8(+) regulatory T cells limits atherosclerosis and tertiary lymphoid organ development.
    Authors: Clement M, Guedj K, Andreata F, Morvan M, Bey L, Khallou-Laschet J, Gaston A, Delbosc S, Alsac J, Bruneval P, Deschildre C, Le Borgne M, Castier Y, Kim H, Cantor H, Michel J, Caligiuri G, Nicoletti A
    Circulation, 2014-12-31;131(6):560-70.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  23. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers.
    Authors: Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, Laghi L, Allavena P, Mantovani A, Marchesi F
    Clin Cancer Res, 2014-02-12;20(8):2147-58.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  24. CXCR5(+) T helper cells mediate protective immunity against tuberculosis.
    Authors: Slight S, Rangel-Moreno J, Gopal R, Lin Y, Fallert Junecko B, Mehra S, Selman M, Becerril-Villanueva E, Baquera-Heredia J, Pavon L, Kaushal D, Reinhart T, Randall T, Khader S
    J Clin Invest, 2013-01-02;123(2):712-26.
    Species: Human, Primate - Macaca mulatta (Rhesus Macaque)
    Sample Types: Whole Tissue
    Applications: IHC-P
  25. Thymic alterations in GM2 gangliosidoses model mice.
    Authors: Kanzaki S, Yamaguchi A, Yamaguchi K, Kojima Y, Suzuki K, Koumitsu N, Nagashima Y, Nagahama K, Ehara M, Hirayasu Y, Ryo A, Aoki I, Yamanaka S
    PLoS ONE, 2010-08-10;5(8):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  26. Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint.
    Arthritis Rheum., 2008-11-01;58(0):3377-87.
    Species: Human
    Sample Types: Whole Cells, Whole Tissue
    Applications: ICC, IHC-P
  27. Interaction of the Lyme disease spirochete Borrelia burgdorferi with brain parenchyma elicits inflammatory mediators from glial cells as well as glial and neuronal apoptosis.
    Authors: Ramesh G, Borda JT, Dufour J, Kaushal D, Ramamoorthy R, Lackner AA, Philipp MT
    Am. J. Pathol., 2008-10-02;173(5):1415-27.
    Species: Primate - Macaca mulatta (Rhesus Macaque)
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  28. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis.
    Authors: Sansonno D, Tucci FA, Troiani L, Lauletta G, Montrone M, Conteduca V, Sansonno L, Dammacco F
    Blood, 2008-06-12;112(5):1620-7.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  29. Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy.
    Authors: Vermijlen D, Ellis P, Langford C, Klein A, Engel R, Willimann K, Jomaa H, Hayday AC, Eberl M
    J. Immunol., 2007-04-01;178(7):4304-14.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  30. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis.
    Authors: Ohshima K, Karube K, Kawano R, Tsuchiya T, Suefuji H, Yamaguchi T, Suzumiya J, Kikuchii M
    Int. J. Oncol., 2004-09-01;25(3):605-13.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  31. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.
    Authors: Casazza S, Zappia E, Pistorio A, Gambini C
    Proc. Natl. Acad. Sci. U.S.A., 2004-07-19;101(30):11064-9.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  32. Developing neonatal rabbit appendix, a primary lymphoid organ, is seeded by immature blood-borne B cells: evidence for roles for CD62L/PNAd, CCR7/CCL21, alpha4beta1 and LFA-1.
    Authors: Sinha RK, Mage RG
    Dev. Comp. Immunol., 2004-06-01;28(7):829-41.
    Species: Rabbit
    Sample Types: Whole Tissue
    Applications: IHC
  33. Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques
    Authors: Mary S. Pampusch, Emily N. Sevcik, Zoe E. Quinn, Brianna C. Davey, James M. Berg, Ian Gorrell-Brown et al.
    Frontiers in Immunology
  34. Differential Expression of Programmed Death-1 (PD-1) in Sézary Syndrome and Mycosis Fungoides
    Authors: Fatma Çetinözman, Patty M. Jansen, Maarten H. Vermeer, Rein Willemze
    Archives of Dermatology
  35. The pathological features of ectopic lymphoid neogenesis in idiopathic dacryoadenitis
    Authors: Jie Guo, Jiang Qian, Rui Zhang
    BMC Ophthalmology
  36. Follicular dendritic cell differentiation is associated with distinct synovial pathotype signatures in rheumatoid arthritis
    Authors: Mohey Eldin M. El Shikh, Riham El Sayed, Nesreen Amer Ramadan Aly, Edoardo Prediletto, Rebecca Hands, Liliane Fossati-Jimack et al.
    Frontiers in Medicine
  37. Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney
    Authors: Yuki Sato, Akiko Mii, Yoko Hamazaki, Harumi Fujita, Hirosuke Nakata, Kyoko Masuda et al.
    JCI Insight
  38. Antibodies to Endothelial Cell Growth Factor and Obliterative Microvascular Lesions in the Synovium of Patients With Antibiotic-Refractory Lyme Arthritis
    Authors: Diana Londoño, Diego Cadavid, Elise E. Drouin, Klemen Strle, Gail McHugh, John M. Aversa et al.
    Arthritis & Rheumatology
  39. The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides
    Authors: Rebecca C. Harris, Kimberly A. Chianese-Bullock, Gina R. Petroni, Jochen T. Schaefer, Louis B. Brill, Kerrington R. Molhoek et al.
    Journal of Immunotherapy

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human CXCL13/BLC/BCA-1 Antibody

Average Rating: 4.8 (Based on 5 Reviews)

5 Star
80%
4 Star
20%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human CXCL13/BLC/BCA-1 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human CXCL13/BLC/BCA-1 Antibody
By Yannick Alexandre on 07/06/2022
Application: Flow Sample Tested: Splenocytes Species: Human

CXCL13 and negative control.

Flow Cytometry Human CXCL13/BLC/BCA-1 Antibody AF801
Human CXCL13/BLC/BCA-1 Antibody
By Yannick Alexandre on 07/06/2022
Application: Immunocytochemistry/Immunofluorescence Sample Tested: Spleen tissue Species: Human

Human spleens fixed in 4% PFA

Immunocytochemistry/Immunofluorescence Human CXCL13/BLC/BCA-1 Antibody AF801
Human CXCL13/BLC/BCA-1 Antibody
By Anonymous on 12/10/2021
Application: IHC Sample Tested: Tonsil tissue Species: Human

Tonsil FFPE section.
Primary Ab: 2ug/mL
Detected using BOND Refine kit
Rabbit anti-goat was used as Post Primary
ER2 retrieval

Immunohistochemistry Human CXCL13/BLC/BCA-1 Antibody AF801
Human CXCL13/BLC/BCA-1 Antibody
By Chi P on 04/23/2018
Application: IHC Sample Tested: Lymph node tissue Species: Rhesus Macaque

The CXCL13 can be observed in blue while CXCR5+ cells are observed in red

Immunohistochemistry Human CXCL13/BLC/BCA-1 Antibody AF801
Human CXCL13/BLC/BCA-1 Antibody
By Anonymous on 03/21/2018
Application: IHC Sample Tested: Spleen tissue Species: Rhesus Macaque